UGC Approved Journal no 63975(19)

ISSN: 2349-5162 | ESTD Year : 2014
Call for Paper
Volume 11 | Issue 4 | April 2024

JETIREXPLORE- Search Thousands of research papers



WhatsApp Contact
Click Here

Published in:

Volume 10 Issue 2
February-2023
eISSN: 2349-5162

UGC and ISSN approved 7.95 impact factor UGC Approved Journal no 63975

7.95 impact factor calculated by Google scholar

Unique Identifier

Published Paper ID:
JETIR2302243


Registration ID:
508598

Page Number

c315-c320

Share This Article


Jetir RMS

Title

Review on Bilastine and Montelukast Used In Treatment on Allergic Condition

Abstract

Allergic disorders are conditions induced by the immune system’s hypersensitivity to normally harmless chemicals known as allergens. The most common allergens include dust mites, pollution, grass pollens and food allergens such as milk, egg, soy, wheat, nut, or fish proteins. Allergic diseases include allergic rhinitis (AR), allergic asthma, urticaria, atopic dermatitis, contact allergies and food allergies. AR is the most common of all atopic diseases, afflicting 10%–30% of adults and up to 40% of children all over the world. The mechanisms underlying AR are highly complex and involve multiple immune cells, mediators and cytokines such as histamine and leukotrienes. It is characterized by nasal symptoms such as sneezing, nasal itching, rhinorrhea, and nasal congestion. It is also, associated with non-nasal symptoms such as watery eyes, redness in the eyes or inflammation. It has a significant effect on one’s health, as well as the quality of one’s sleep, work productivity and academic performance. The management of AR includes allergen avoidance, pharmacotherapy, and immunotherapy. Complete avoidance of allergens that trigger AR symptoms is not possible. Current pharmacologic options include antihistamines (oral and intranasal), Leukotriene Receptor Antagonists (LTRAs), Intranasal Corticosteroids (INCS), decongestants and oral and intranasal anticholinergics. Amongst other antihistamines, Bilastine has emerged as a new, non-sedating and well-tolerated antihistamine while Montelukast is an effective add-on LTRA option to an antihistamine with well-established literature in the management of moderate severe AR. Immunotherapy is a treatment option for patients who have not responded to medication.

Key Words

Allergic rhinitis, antihistamines, LTRAs, Montelukast, Bilastine

Cite This Article

"Review on Bilastine and Montelukast Used In Treatment on Allergic Condition", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.10, Issue 2, page no.c315-c320, February-2023, Available :http://www.jetir.org/papers/JETIR2302243.pdf

ISSN


2349-5162 | Impact Factor 7.95 Calculate by Google Scholar

An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 7.95 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator

Cite This Article

"Review on Bilastine and Montelukast Used In Treatment on Allergic Condition", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.10, Issue 2, page no. ppc315-c320, February-2023, Available at : http://www.jetir.org/papers/JETIR2302243.pdf

Publication Details

Published Paper ID: JETIR2302243
Registration ID: 508598
Published In: Volume 10 | Issue 2 | Year February-2023
DOI (Digital Object Identifier):
Page No: c315-c320
Country: Ashti , Maharashtra, India .
Area: Pharmacy
ISSN Number: 2349-5162
Publisher: IJ Publication


Preview This Article


Downlaod

Click here for Article Preview

Download PDF

Downloads

00094

Print This Page

Current Call For Paper

Jetir RMS